Semaglutide for Cardiovascular Disease
SELECT trial: semaglutide reduced major cardiac events by 20% in non-diabetic patients with CVD and obesity. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist shown to produce 15% average body weight loss in clinical trials.
How Semaglutide Helps with Cardiovascular Disease
Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with cardiovascular disease, this weight loss translates to meaningful improvements in condition-specific outcomes.
SELECT trial: semaglutide reduced major cardiac events by 20% in non-diabetic patients with CVD and obesity. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.
Clinical Evidence for Cardiovascular Disease
Cardiovascular Disease affects 121 million US adults have some form of CVD. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with cardiovascular disease. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.
Semaglutide Dosing for Cardiovascular Disease
Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.
Cost of Semaglutide for Cardiovascular Disease
Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with cardiovascular disease have associated comorbidities that improve insurance coverage chances.